Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Breast Neoplasms 3Triple Negative Breast Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2rrCLL 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Lymphoma, Mantle-Cell 1Leukemia, Prolymphocytic 1Leukemia, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Advanced Malignant Solid Neoplasm 1

Interventions

Rituximab 344Cyclophosphamide 317fludarabine phosphate 142Etoposide 139Peripheral Blood Stem Cell Transplantation 124fludarabine 112Filgrastim 112Mycophenolic Acid 98Melphalan 98Whole-Body Irradiation 90Vincristine 90Busulfan 87Cytarabine 85Doxorubicin 79Cyclosporine 76Tacrolimus 75Radiotherapy 75Prednisone 73Bendamustine Hydrochloride 72Granulocyte Colony-Stimulating Factor 66Methotrexate 65Antilymphocyte Serum 56Carmustine 54Dexamethasone 50Gemcitabine 48Lenalidomide 46Bortezomib 43venetoclax 41ibritumomab tiuxetan 37obinutuzumab 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × dinaciclib × Clear all
NCT00871910 2017-10-23

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

Merck Sharp & Dohme LLC

Phase 1 Completed
81 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT00871663 2015-04-20

Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

Merck Sharp & Dohme LLC

Phase 1 Completed
123 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡